A Prospective, Self-controlled Study to Explore Efficacy and Safety of Orelabrutinib in AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Latest Information Update: 07 Mar 2024
At a glance
- Drugs Orelabrutinib (Primary)
- Indications Neuromyelitis optica
- Focus Therapeutic Use
Most Recent Events
- 22 Mar 2022 New trial record